NCT01407562View on ClinicalTrials.gov

Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

September 17, 2010

Primary Completion Date

March 29, 2016

Study Completion Date

March 29, 2016

Conditions
Unspecified Adult Solid Tumor - Protocol SpecificBreast Cancer - Female
Interventions
DRUG

Pazopanib

Starting dose is 400 given on Days 2-5, 9-12, and 16-26 of each 28 day cycle

DRUG

Paclitaxel

Starting dose is 60 mg/m2 IV on days 1, 8, and 15 of each 28 day cycle

DRUG

Carboplatin

Starting dose of carboplatin that corresponds to an AUC of 2, IV on days 1, 8, and 15 of each 28 day cycle

Trial Locations (1)

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Rutgers Cancer Institute of New Jersey

OTHER

collaborator

GlaxoSmithKline

INDUSTRY

lead

Rutgers, The State University of New Jersey

OTHER